AFP and neoplasm: Among separate groups, absent AE (p = 0.008), lower AFP (p = 0.014), tumor numbers ≤ 3 (p = 0.032), and sorafenib duration ≤ 1 cycle (p = 0.003) presented significant difference affecting patient’s survival.